JP2022530599A5 - - Google Patents

Info

Publication number
JP2022530599A5
JP2022530599A5 JP2021545411A JP2021545411A JP2022530599A5 JP 2022530599 A5 JP2022530599 A5 JP 2022530599A5 JP 2021545411 A JP2021545411 A JP 2021545411A JP 2021545411 A JP2021545411 A JP 2021545411A JP 2022530599 A5 JP2022530599 A5 JP 2022530599A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
seq
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021545411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530599A (ja
JP7240512B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/034000 external-priority patent/WO2021242728A1/en
Publication of JP2022530599A publication Critical patent/JP2022530599A/ja
Priority to JP2022179201A priority Critical patent/JP2023011902A/ja
Publication of JP2022530599A5 publication Critical patent/JP2022530599A5/ja
Application granted granted Critical
Publication of JP7240512B2 publication Critical patent/JP7240512B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021545411A 2020-05-26 2021-05-25 Pd-1阻害剤を投与することにより子宮頸がんを処置する方法 Active JP7240512B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022179201A JP2023011902A (ja) 2020-05-26 2022-11-09 Pd-1阻害剤を投与することにより子宮頸がんを処置する方法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063029757P 2020-05-26 2020-05-26
US63/029,757 2020-05-26
US202063069942P 2020-08-25 2020-08-25
US63/069,942 2020-08-25
US202163160074P 2021-03-12 2021-03-12
US63/160,074 2021-03-12
US202163174474P 2021-04-13 2021-04-13
US63/174,474 2021-04-13
US202163181434P 2021-04-29 2021-04-29
US63/181,434 2021-04-29
US202163185881P 2021-05-07 2021-05-07
US63/185,881 2021-05-07
PCT/US2021/034000 WO2021242728A1 (en) 2020-05-26 2021-05-25 Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022179201A Division JP2023011902A (ja) 2020-05-26 2022-11-09 Pd-1阻害剤を投与することにより子宮頸がんを処置する方法

Publications (3)

Publication Number Publication Date
JP2022530599A JP2022530599A (ja) 2022-06-30
JP2022530599A5 true JP2022530599A5 (cg-RX-API-DMAC7.html) 2022-11-29
JP7240512B2 JP7240512B2 (ja) 2023-03-15

Family

ID=76859703

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021545411A Active JP7240512B2 (ja) 2020-05-26 2021-05-25 Pd-1阻害剤を投与することにより子宮頸がんを処置する方法
JP2022179201A Pending JP2023011902A (ja) 2020-05-26 2022-11-09 Pd-1阻害剤を投与することにより子宮頸がんを処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022179201A Pending JP2023011902A (ja) 2020-05-26 2022-11-09 Pd-1阻害剤を投与することにより子宮頸がんを処置する方法

Country Status (11)

Country Link
US (1) US20210403567A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157464A1 (cg-RX-API-DMAC7.html)
JP (2) JP7240512B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230015954A (cg-RX-API-DMAC7.html)
CN (1) CN115666724A (cg-RX-API-DMAC7.html)
AU (1) AU2021280245A1 (cg-RX-API-DMAC7.html)
CA (1) CA3168738A1 (cg-RX-API-DMAC7.html)
IL (1) IL298273A (cg-RX-API-DMAC7.html)
MX (1) MX2022014734A (cg-RX-API-DMAC7.html)
TW (1) TWI899236B (cg-RX-API-DMAC7.html)
WO (1) WO2021242728A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240043560A1 (en) * 2022-08-02 2024-02-08 Regeneron Pharmaceuticals, Inc. Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 Antibodies
TWI887800B (zh) * 2022-10-12 2025-06-21 美商默沙東有限責任公司 經由皮下投予抗pd1抗體以治療癌症之組合物及方法
WO2026158432A1 (zh) * 2025-01-24 2026-07-30 江苏奥赛康生物医药有限公司 抗pd-1抗体-il-15前药的融合分子与化学治疗药物的组合及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
ES2742379T3 (es) 2012-05-31 2020-02-14 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US10241115B2 (en) 2013-12-10 2019-03-26 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
PT3134123T (pt) * 2014-02-21 2021-03-22 Nektar Therapeutics India Pvt Ltd Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1
SG10201901057UA (en) 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3254110B1 (en) 2015-02-03 2020-03-18 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
IL261998B2 (en) 2016-04-07 2023-03-01 Chemocentryx Inc Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JP7348072B2 (ja) * 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法

Similar Documents

Publication Publication Date Title
AU2012236479B2 (en) Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
JP2020508317A5 (cg-RX-API-DMAC7.html)
IL317348A (en) Stable formulations of PROGRAMMED DEATH RECEPTOR 1 (PD–1) antibodies and methods of using them
CN111132696B (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
TW201922793A (zh) Pd-1抗體和vegfr抑制劑聯合治療小細胞肺癌的用途
IL321717A (en) Anti-PD-1 antibodies for the treatment of lung cancer
KR102104296B1 (ko) 종양성 질병들에 대한 치료
JP2018515493A5 (cg-RX-API-DMAC7.html)
CN108079292A (zh) 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
EP3463453A1 (en) Combination of pembrolizumab and abemaciclib for the treatment of cancer
TW201922273A (zh) 用於治療肝癌之組合物及方法
JP2022513029A5 (cg-RX-API-DMAC7.html)
CN109663130B (zh) Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
JP7240512B2 (ja) Pd-1阻害剤を投与することにより子宮頸がんを処置する方法
CN109806393B (zh) 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途
JP2023500480A5 (cg-RX-API-DMAC7.html)
WO2017176565A1 (en) Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
CN110013552B (zh) 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
TWI814752B (zh) 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途
KR20200105825A (ko) 삼중 음성 유방암의 치료를 위한 pd-1 항체 및 아파티닙의 조합 치료의 용도
WO2026022216A1 (en) Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases
WO2026021442A1 (zh) 抗体药物偶联物在制备治疗肺癌的药物中的用途
JP2024536201A5 (cg-RX-API-DMAC7.html)
TH137483A (th) การรักษาโดยการยับยั้งการเกิดเส้นเลือดใหม่ (anti-angiogenesis therapy) สำหรับบำบัดมะเร็งรังไข่ (ovarian cancer)